TARO 151.28 Taro Pharm Inds $TARO Hit a 52 week high of 155.00 Currently at 151.28 -3.28 -2.12% With a day low of 151.28 and a total volume of 3,411.
TARO Taro Pharm Inds Recent Headline News
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 148.99 (-5.57)
Taro Pharma ups earnings 49% in FQ2
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:48PM CST
TARO: 148.99 (-5.57)
Taro Pharmaceutical EPS of $3.35
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:43AM CST
TARO: 148.99 (-5.57)
Taro Provides Results for September 30, 2014
Business Wire - Sun Nov 09, 10:36AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and six months ended September 30, 2014.
TARO: 148.99 (-5.57)
Taro reports November 9
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
TARO: 148.99 (-5.57)
Taro to Announce Second Quarter Results on November 9, 2014
Business Wire - Wed Nov 05, 2:26PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.
TARO: 148.99 (-5.57)
Use The Relative Strength Line To Qualify A Breakout
at Investor's Business Daily - Wed Oct 29, 5:40PM CDT
Stock charts are a collection of facts and tools: price, volume, moving averages. All of them help you understand how a stock and its investors are responding to market input and supply and demand. One very helpful but often lesser-used tool is the...
TARO: 148.99 (-5.57)
Glaucoma Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qn2l4v/glaucoma_market) has announced the addition of the "Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Merck & Co., Inc. - Alcon, Inc. - Taro Pharmaceutical Industries Ltd. - Pharmacia & Upjohn, Inc. - Teva Pharmaceuticals USA, Inc. - Akorn, Inc. - Pfizer Inc. - Alcon Laboratories, Inc. - Bausch & Lomb Incorporated - JHP Pharmaceuticals, LLC - Mobius Therapeutics, LLC - American Regent, Inc. For more information visit http://www.researchandmarkets.com/research/qn...oma_market
AGN: 195.73 (+0.49), TARO: 148.99 (-5.57), AKRX: 35.09 (-1.07), PFE: 30.26 (+0.06), MRK: 59.26 (+0.45)
Taro Provides Results for Quarter Ended June 2014
Business Wire - Thu Aug 07, 5:47PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the three month period ended June 30, 2014.
TARO: 148.99 (-5.57)
Taro to Announce Results for Quarter Ended June 30, 2014
Business Wire - Mon Aug 04, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2014 after market close on Thursday, August 7, 2014.
TARO: 148.99 (-5.57)
4 Stocks Spiking on Big Volume
at The Street - Thu Jul 31, 8:03AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
TARO: 148.99 (-5.57), PNRA: 168.25 (-1.06), EPAY: 25.25 (-0.21), EEFT: 55.16 (-0.20)
Israel's Market Appears Unfazed By Rising Conflict
at Investor's Business Daily - Tue Jul 22, 5:07PM CDT
The conflict between Israel and Palestinians caused the U.S. Federal Aviation Administration on Tuesday to temporarily ban American flights to and from Tel Aviv's Ben Gurion International Airport after a rocket landed near the facility. The airport...
PRGO: 155.39 (-1.17), CSTE: 60.06 (+0.59), EIS: 48.82 (-0.40), TARO: 148.99 (-5.57), ISRA: 30.53 (-0.37), TSEM: 10.21 (-0.01), TEVA: 58.20 (+0.16), MLNX: 44.00 (-0.44), CHKP: 74.99 (+0.26)
Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available
Business Wire - Tue Jul 08, 6:42PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro" announced that its Annual Report for fiscal year ended March 31, 2014 on Form 20-F, filed with the Securities and Exchange Commission (the "SEC" , is available within the Investor Relations section of Taro's website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to Taro Pharmaceuticals U.S.A., Inc., Three Skyline Drive, Hawthorne, NY 10532, attention: William J. Coote or via email to William.Coote@Taro.com.
TARO: 148.99 (-5.57)
NYSE stocks posting largest percentage increases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
BTH: 9.06 (-0.07), NWHM: 14.49 (-0.09), SFE: 19.77 (-0.33), TRR: 7.17 (+0.04), AZZ: 45.98 (-0.47), EGO: 5.83 (+0.53), TARO: 148.99 (-5.57), ELD.TO: 6.62 (+0.59), PKE: 26.26 (-0.12), MTW: 21.40 (-0.07), GNI: 20.74 (-0.36)
Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
ACT: 243.19 (-2.54), MYGN: 32.13 (-0.67), NVO: 44.27 (+0.97), TARO: 148.99 (-5.57), SLXP: 97.46 (+3.59), ILMN: 187.87 (-0.40), MYL: 53.60 (-0.35)
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
TARO: 148.99 (-5.57), ABBV: 63.66 (-0.13), FMS: 36.37 (+0.08)
Why I'm Avoiding Taro Pharmaceuticals
Nathaniel Calloway, The Motley Fool - Motley Fool - Fri Jun 13, 4:14PM CDT
Based purely on financial metrics, Taro Pharmaceuticals looks like a great investment. Taro is Israeli generic and branded pharmaceutical maker focused primarily on dermatology and skincare that has been undergoing unprecedented growth in the...
TARO: 148.99 (-5.57)
Taro Announces Results of Its Extraordinary General Meeting of Shareholders
Business Wire - Thu Mar 27, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" announced that the Company held an extraordinary general meeting of shareholders today, March 27, 2014, at 14 Hakitor Street, Haifa Bay 26110, Israel (the "Extraordinary General Meeting" . IVS Associates, Inc., a leading provider of independent election services, independently tabulated and certified the voting results of the Extraordinary General Meeting.
TARO: 148.99 (-5.57)
TARO Taro Pharm Inds Recent Headline News
Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q2 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:07PM CST
TARO: 148.99 (-5.57)
Taro Pharma ups earnings 49% in FQ2
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:48PM CST
TARO: 148.99 (-5.57)
Taro Pharmaceutical EPS of $3.35
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:43AM CST
TARO: 148.99 (-5.57)
Taro Provides Results for September 30, 2014
Business Wire - Sun Nov 09, 10:36AM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three months and six months ended September 30, 2014. TARO: 148.99 (-5.57)
Taro reports November 9
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
TARO: 148.99 (-5.57)
Taro to Announce Second Quarter Results on November 9, 2014
Business Wire - Wed Nov 05, 2:26PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday, November 9, 2014.
TARO: 148.99 (-5.57)
Use The Relative Strength Line To Qualify A Breakout
at Investor's Business Daily - Wed Oct 29, 5:40PM CDT
Stock charts are a collection of facts and tools: price, volume, moving averages. All of them help you understand how a stock and its investors are responding to market input and supply and demand. One very helpful but often lesser-used tool is the...
TARO: 148.99 (-5.57)
Glaucoma Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qn2l4v/glaucoma_market) has announced the addition of the "Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Glaucoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Merck & Co., Inc. - Alcon, Inc. - Taro Pharmaceutical Industries Ltd. - Pharmacia & Upjohn, Inc. - Teva Pharmaceuticals USA, Inc. - Akorn, Inc. - Pfizer Inc. - Alcon Laboratories, Inc. - Bausch & Lomb Incorporated - JHP Pharmaceuticals, LLC - Mobius Therapeutics, LLC - American Regent, Inc. For more information visit http://www.researchandmarkets.com/research/qn...oma_market
AGN: 195.73 (+0.49), TARO: 148.99 (-5.57), AKRX: 35.09 (-1.07), PFE: 30.26 (+0.06), MRK: 59.26 (+0.45)
Taro Provides Results for Quarter Ended June 2014
Business Wire - Thu Aug 07, 5:47PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three month period ended June 30, 2014. TARO: 148.99 (-5.57)
Taro to Announce Results for Quarter Ended June 30, 2014
Business Wire - Mon Aug 04, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2014 after market close on Thursday, August 7, 2014.
TARO: 148.99 (-5.57)
4 Stocks Spiking on Big Volume
at The Street - Thu Jul 31, 8:03AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
TARO: 148.99 (-5.57), PNRA: 168.25 (-1.06), EPAY: 25.25 (-0.21), EEFT: 55.16 (-0.20)
Israel's Market Appears Unfazed By Rising Conflict
at Investor's Business Daily - Tue Jul 22, 5:07PM CDT
The conflict between Israel and Palestinians caused the U.S. Federal Aviation Administration on Tuesday to temporarily ban American flights to and from Tel Aviv's Ben Gurion International Airport after a rocket landed near the facility. The airport...
PRGO: 155.39 (-1.17), CSTE: 60.06 (+0.59), EIS: 48.82 (-0.40), TARO: 148.99 (-5.57), ISRA: 30.53 (-0.37), TSEM: 10.21 (-0.01), TEVA: 58.20 (+0.16), MLNX: 44.00 (-0.44), CHKP: 74.99 (+0.26)
Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available
Business Wire - Tue Jul 08, 6:42PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro"
announced that its Annual Report for fiscal year ended March 31, 2014 on Form 20-F, filed with the Securities and Exchange Commission (the "SEC" , is available within the Investor Relations section of Taro's website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to Taro Pharmaceuticals U.S.A., Inc., Three Skyline Drive, Hawthorne, NY 10532, attention: William J. Coote or via email to William.Coote@Taro.com. TARO: 148.99 (-5.57)
NYSE stocks posting largest percentage increases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
BTH: 9.06 (-0.07), NWHM: 14.49 (-0.09), SFE: 19.77 (-0.33), TRR: 7.17 (+0.04), AZZ: 45.98 (-0.47), EGO: 5.83 (+0.53), TARO: 148.99 (-5.57), ELD.TO: 6.62 (+0.59), PKE: 26.26 (-0.12), MTW: 21.40 (-0.07), GNI: 20.74 (-0.36)
Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
ACT: 243.19 (-2.54), MYGN: 32.13 (-0.67), NVO: 44.27 (+0.97), TARO: 148.99 (-5.57), SLXP: 97.46 (+3.59), ILMN: 187.87 (-0.40), MYL: 53.60 (-0.35)
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
TARO: 148.99 (-5.57), ABBV: 63.66 (-0.13), FMS: 36.37 (+0.08)
Why I'm Avoiding Taro Pharmaceuticals
Nathaniel Calloway, The Motley Fool - Motley Fool - Fri Jun 13, 4:14PM CDT
Based purely on financial metrics, Taro Pharmaceuticals looks like a great investment. Taro is Israeli generic and branded pharmaceutical maker focused primarily on dermatology and skincare that has been undergoing unprecedented growth in the...
TARO: 148.99 (-5.57)
Taro Announces Results of Its Extraordinary General Meeting of Shareholders
Business Wire - Thu Mar 27, 4:05PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
announced that the Company held an extraordinary general meeting of shareholders today, March 27, 2014, at 14 Hakitor Street, Haifa Bay 26110, Israel (the "Extraordinary General Meeting" . IVS Associates, Inc., a leading provider of independent election services, independently tabulated and certified the voting results of the Extraordinary General Meeting. TARO: 148.99 (-5.57)
